Wockhardt, a global pharmaceutical company, has expanded into the Middle East with the opening of a $40 million state-of-the-art facility for manufacturing new chemical entities (NCEs) in Jebel Ali Free Zone (Jafza) in Dubai, UAE.
The ‘state-of-the-art’ manufacturing facility meant for the production and packaging of sterile dry powder injection. On approval of the new drug by US FDA, this manufacturing facility will be commissioned for commercial production.
Wockhardt currently has five novel antibiotic drugs in advanced stages of global clinical development which will be effective against these “superbugs” threats identified by the Center of Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDA has granted Qualified Infectious Disease Program (QIDP) status to the five novel antibiotic drugs.
The 10,000-sq-m facility in Dubai is equipped with best-in-class and fully automated manufacturing equipment, creating a self-sufficient environment for handling, warehousing, manufacturing operations, product testing and product stability. The facility meets the needs of Aseptic Dry Powder Injectable manufacturing and filling with a high-quality operation. This facility is dedicated to launch its novel New Chemical Entities in the antibiotics segment to the world from UAE.
Wockhardt is a global pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe. Wockhardt also has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.